Exact Mass: 662.3335804000001
Exact Mass Matches: 662.3335804000001
Found 190 metabolites which its exact mass value is equals to given mass value 662.3335804000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Prosapogenin
Saponin from peel of Quillaja saponaria (soap-bark tree). Saponin from peel of Quillaja saponaria (soap-bark tree)
1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside
1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside is found in fruits. 1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). 1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside is found in fruits.
Physalolactone B 3-glucoside
Physalolactone B 3-glucoside is found in fruits. Physalolactone B 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). Physalolactone B 3-glucoside is found in fruits.
PA(10:0/PGF2alpha)
C33H59O11P (662.3794793999999)
PA(10:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGF2alpha), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF2alpha/10:0)
C33H59O11P (662.3794793999999)
PA(PGF2alpha/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/10:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/PGE1)
C33H59O11P (662.3794793999999)
PA(10:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGE1), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE1/10:0)
C33H59O11P (662.3794793999999)
PA(PGE1/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/10:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/PGD1)
C33H59O11P (662.3794793999999)
PA(10:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGD1), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD1/10:0)
C33H59O11P (662.3794793999999)
PA(PGD1/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/10:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(12:0/5-iso PGF2VI)
C33H59O11P (662.3794793999999)
PA(12:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/5-iso PGF2VI), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/12:0)
C33H59O11P (662.3794793999999)
PA(5-iso PGF2VI/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/12:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-12:0/5-iso PGF2VI)
C33H59O11P (662.3794793999999)
PA(i-12:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/5-iso PGF2VI), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/i-12:0)
C33H59O11P (662.3794793999999)
PA(5-iso PGF2VI/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/i-12:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
1beta,8alpha-diacetoxy-9beta-benzoyloxy-4alpha,6alpha-dihydroxy-2beta,13-diisobutanoyloxy-beta-dihydroagafuran
protoconstipatic acid (18S)-18-O-alpha-D-arabinofuranosyl-(1-6)-beta-D-glucopyranoside
3-O-beta-D-Glucopyranuronoside-3-Hydroxy-12-oleanene-23,28-dioic acid
cis-Cleroda-3,13(14)-dien-15,16-olide-18-O-[??-D-galactopyranosyl]-peracetylester
alo-murolic acid (18R)-18-O-1-beta-xylopyranosyl-(1-6)-beta-D-glucopyranoside
2-{[2,4,6-trihydroxy-5-(3,7-dimethyl-2,6-octadienyl)-3-butanoylphenyl]methyl}-3,5-dihydroxy-4-methyl-4-(3,7-dimethyl-2,6-octadienyl)-6-acetyl-2,5-cyclohexadien-1-one|yungensin E
16-decarbomethoxyvoacamine-pseudoindoxyl
C41H50N4O4 (662.3831859999999)
murolic acid (18R)-18-O-beta-D-apiofuranosyl-(1-2)-beta-D-glucopyranoside
(3beta,5alpha,6beta,15alpha,22E,24R)-Cholest-4-ene-3,6,8,15,24-pentol
C32H54O12S (662.3335804000001)
protoconstipatic acid (18S)-18-O-beta-D-apiofuranosyl-(1-4)-beta-D-glucopyranoside
(1R)-1alpha,11alpha,22alpha-trihydroxy-3,4-seco-lupa-4(23),20(30)-diene-3,28-dioic acid3,11-lactone 28-O-beta-D-glucopyranoside|acanthosessilioside F
gnidilatimonoein
A diterpenoid isolated from the leaves of Daphne mucronata and exhibits anti-tumour and anti-metastatic activities.
3beta,24-dihydroxy-22-oxo-12-oleanen-29-oic acid 3-O-beta-D-glucuropyranoside|caraganin B
(3beta,6alpha,15beta,24S)-Cholest-4-ene-3,6,8,15,24-pentol
C32H54O12S (662.3335804000001)
1alpha,2alpha-diacetoxy-9alpha-benzoyloxy-4beta,6beta-dihydroxy-8beta,13-bis(isobutanoyloxy)-beta-dihydroagarofuran|angulatin A|angulatrin A|celangulin V
allo-murolic acid (18R)-18-O-beta-D-apiofuranosyl-(1-6)-beta-D-glucopyranoside
3beta,3,30-dihydroxyursa-12,19-diene-24,28-dioic acid 28-O-beta-D-glucopyranoside|ilexhainanoside B
butyl 3-O-butanoyl-4,6,4-tri(O-2-methylpropanoyl)neohesperidoside
PicfeltarraeninX
Angulatin A
1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside
Physalolactone B 3-glucoside
prosapogenin
15-(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyloxy)hexadecanoic acid 1,4-lactone 6,6-diacetate
16-(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyloxy)hexadecanoic acid 1,4-lactone 6,6-diacetate
OHDdiA-PA
C33H59O11P (662.3794793999999)
Evasterioside B
C32H54O12S (662.3335804000001)
Butyl 3-O-butanoyl-4,6,4-tri-O-(2-methylpropanoyl)-neohesperidoside
Zirconium(2+) bis(2-ethylhexanoate)
C32H60O8Zr (662.3335040000001)
(1R,2R)-N1,N2-BIS(2-(DIPHENYLPHOSPHINO)BENZYL)CYCLOHEXANE-1,2-DIAMINE
C44H44N2P2 (662.2979564000001)
2-[2-[3-[2-(3,3-dimethyl-1-phenylindol-1-ium-2-yl)ethenyl]-2H-pyran-5-ylidene]ethylidene]-3,3-dimethyl-1-phenylindole,tetrafluoroborate
C41H39BF4N2O (662.3091402000001)
N-[[(3S,9S,10S)-16-[[(4-fluoroanilino)-oxomethyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-2-phenylacetamide
C37H47FN4O6 (662.3479454000001)
L-leucyl-L-seryl-L-alpha-glutamyl-L-threonyl-L-threonyl-D-leucine
[(3S,5S,6R,8S,9R,10S,13R,14S,15S,17R)-6,8,15-trihydroxy-10,13-dimethyl-17-[(E,2R)-6-methyl-5-[(2S,3S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyhept-3-en-2-yl]-1,2,3,4,5,6,7,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
C32H54O12S (662.3335804000001)
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
2-[[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
(4as,5r,6s,8ar,9ar)-9a-[(4as,5r,6s,8ar,9ar)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-6-yl (2z)-2-methylbut-2-enoate
(4as,5r,6s,8ar,9as)-9a-[(4as,5r,6s,8ar,9as)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-6-yl (2z)-2-methylbut-2-enoate
2-[(2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-[(2,6,10-trimethyldodeca-2,6,10-trien-1-yl)oxy]oxan-3-yl]oxy}-4,5-dihydroxy-6-methyloxan-3-yl)oxy]oxane-3,4,5-triol
2-{14-[(3-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]pentadecyl}-4-methylidene-5-oxooxolane-3-carboxylic acid
(2r)-n-[(2s)-1-[(1r,9r,10s,11r,12r)-1,12-dihydroxy-9-(3-hydroxy-4-methoxyphenyl)-3,5-dimethoxy-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl]-2-hydroxy-2-methylbutanimidic acid
2-phenyl-n-[(2r,3s)-4,7,10-trihydroxy-6,9-bis(1h-indol-3-ylmethyl)-2-methyl-14-oxo-1-oxa-5,8,11-triazacyclotetradeca-4,7,10-trien-3-yl]ethanimidic acid
methyl (1s,12r,14s,18s)-12-[(1's,2s,3'r,8's,9's)-9'-ethyl-5-methoxy-3-oxo-1h-7'-azaspiro[indole-2,4'-tricyclo[5.3.1.0³,⁸]undecan]-6-yl]-15-ethylidene-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
C41H50N4O4 (662.3831859999999)
3',19-dihydroxyaglaine c
{"Ingredient_id": "HBIN006973","Ingredient_name": "3',19-dihydroxyaglaine c","Alias": "NA","Ingredient_formula": "C36H42N2O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5752","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2r,3s,4s,5r)-6-({2-[(1ar,2r,4ar,7r,8ar)-2,7-dihydroxy-4a-methyl-8-methylidene-hexahydronaphtho[1,8a-b]oxiren-2-yl]propan-2-yl}oxy)-2-methyl-5-{[(2z)-2-methylbut-2-enoyl]oxy}-4-[(2-methylbutanoyl)oxy]oxan-3-yl (2z)-2-methylbut-2-enoate
(2r,3r,4s,5s,6r)-2-{[(1r,4s,5r,9r,10s,13r,14r,15r)-14-hydroxy-14-(hydroxymethyl)-5,9-dimethyl-15-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r)-2-[(14s)-14-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
2-acetyl-6-{[3-butanoyl-5-(3,7-dimethylocta-2,6-dien-1-yl)-2,4,6-trihydroxyphenyl]methyl}-4-(3,7-dimethylocta-2,6-dien-1-yl)-3,5-dihydroxy-4-methylcyclohexa-2,5-dien-1-one
4,5-bis(acetyloxy)-2,12-dihydroxy-2,10,10-trimethyl-8-[(2-methylpropanoyl)oxy]-6-{[(2-methylpropanoyl)oxy]methyl}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
2-{[14-hydroxy-14-(hydroxymethyl)-5,9-dimethyl-15-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3s,4s,5s)-2-{[(2s,3s,4s,5r,6s)-2-{[(2s,3r,4s,5s,6s)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(2e,6e,10e)-2,6,10-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-6-methyloxan-3-yl]oxy}oxane-3,4,5-triol
methyl (1s,12r,14s,15e,18s)-12-[(1's,2s,3'r,8's,9's)-9'-ethyl-5-methoxy-3-oxo-1h-7'-azaspiro[indole-2,4'-tricyclo[5.3.1.0³,⁸]undecan]-6-yl]-15-ethylidene-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
C41H50N4O4 (662.3831859999999)
9a-{3,4a,5-trimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl}-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-6-yl 2-methylbut-2-enoate
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,5s,6s,8r,9r,10r,12r,16r,17s,18s,21s)-6,16-dihydroxy-1,2,17-trimethyl-14-oxo-8,18-bis(prop-1-en-2-yl)-13-oxapentacyclo[10.8.1.0²,¹⁰.0⁵,⁹.0¹⁷,²¹]henicosane-5-carboxylate
(1r,2r,3as,3bs,9br,11ar)-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,4e)-2,3,6-trihydroxy-6-methylhept-4-en-2-yl]-1h,2h,3h,3bh,11h-cyclopenta[a]phenanthren-10-one
(2e,6e,8z)-10-{9-butyl-8-[(3e)-4-carboxy-3-methylbut-3-en-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl}-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(2s,3s,4s,5r,6r)-6-{[(3s,4s,4ar,6ar,6bs,8ar,12s,12as,14ar,14br)-8a-carboxy-4-formyl-12-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
(1s,2s,4s,5r,6s,7s,8s,9s,12r)-5,8-bis(acetyloxy)-2,12-dihydroxy-2,10,10-trimethyl-4-[(2-methylpropanoyl)oxy]-6-{[(2-methylpropanoyl)oxy]methyl}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(10s)-4-{2-[(10s)-6,6,10,12,12,14-hexamethyl-5,13-dioxo-2-thia-7,11-diazatricyclo[8.4.0.0³,⁸]tetradeca-1(14),3,7-trien-4-yl]ethyl}-6,6,10,12,12,14-hexamethyl-2-thia-7,11-diazatricyclo[8.4.0.0³,⁸]tetradeca-1(14),3,7-triene-5,13-dione
6-[(8a-carboxy-4-formyl-12-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
(1r,3as,3bs,7r,9s,9ar,9bs,11as)-1-[(1s)-1-[(2r)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl acetate
n-[2-({[(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-4,16-dihydroxy-8-(2-hydroxyphenoxy)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]methoxycarboximidic acid
C37H46N2O9 (662.3203146000001)
2-({2-butoxy-4-hydroxy-5-[(2-methylpropanoyl)oxy]-6-{[(2-methylpropanoyl)oxy]methyl}oxan-3-yl}oxy)-3-hydroxy-6-methyl-5-[(2-methylpropanoyl)oxy]oxan-4-yl butanoate
(4r)-2-acetyl-6-({3-butanoyl-5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4,6-trihydroxyphenyl}methyl)-4-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,5-dihydroxy-4-methylcyclohexa-2,5-dien-1-one
n-{1-[1,12-dihydroxy-9-(3-hydroxy-4-methoxyphenyl)-3,5-dimethoxy-10-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-11-carbonyl]pyrrolidin-2-yl}-2-hydroxy-2-methylbutanimidic acid
5,8-bis(acetyloxy)-2,12-dihydroxy-2,10,10-trimethyl-4-[(2-methylpropanoyl)oxy]-6-{[(2-methylpropanoyl)oxy]methyl}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
11-chloro-23-hydroxy-12,20,21-trimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1¹⁰,¹⁴.0³,⁵]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 3-methylbutanoate
C34H47ClN2O9 (662.2969922000001)
(1s,2s,4s,5r,6s,7s,8s,9s,12r)-4,5-bis(acetyloxy)-2,12-dihydroxy-2,10,10-trimethyl-8-[(2-methylpropanoyl)oxy]-6-{[(2-methylpropanoyl)oxy]methyl}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(2s,3r)-2-[(14s)-14-{[(2r,3r,4r,5s,6r)-5-{[(3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
n-[2-({[11-ethyl-4,16-dihydroxy-8-(2-hydroxyphenoxy)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]methoxycarboximidic acid
C37H46N2O9 (662.3203146000001)
(10s)-4-{2-[(10r)-6,6,10,12,12,14-hexamethyl-5,13-dioxo-2-thia-7,11-diazatricyclo[8.4.0.0³,⁸]tetradeca-1(14),3,7-trien-4-yl]ethyl}-6,6,10,12,12,14-hexamethyl-2-thia-7,11-diazatricyclo[8.4.0.0³,⁸]tetradeca-1(14),3,7-triene-5,13-dione
[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2r,3e,5r)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}hept-3-en-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid
C32H54O12S (662.3335804000001)
[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2s,3e,5r)-6-methyl-5-{[(2r,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}hept-3-en-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid
C32H54O12S (662.3335804000001)
(1s,2s,3s,7s,8r,9r,10s,11r,12z,14s,17r)-2,7,9-tris(acetyloxy)-10-(butanoyloxy)-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadeca-4,12-dien-11-yl butanoate
(2s,3s)-2-[(14r)-14-{[(2r,3r,4s,5s,6r)-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}pentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
2-({[2-(5-carboxypentyl)-6-hydroxy-10-methoxy-9-methyl-3-oxo-1,4,8-trioxaspiro[4.5]decan-7-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid
(10r)-4-{2-[(10r)-6,6,10,12,12,14-hexamethyl-5,13-dioxo-2-thia-7,11-diazatricyclo[8.4.0.0³,⁸]tetradeca-1(14),3,7-trien-4-yl]ethyl}-6,6,10,12,12,14-hexamethyl-2-thia-7,11-diazatricyclo[8.4.0.0³,⁸]tetradeca-1(14),3,7-triene-5,13-dione
(1s,2r,3s,5s,6s,16e,18e,20r,21s)-11-chloro-23-hydroxy-12,20,21-trimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1¹⁰,¹⁴.0³,⁵]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 3-methylbutanoate
C34H47ClN2O9 (662.2969922000001)